United States· US:0069-0334_09443f87-c2da-46a4-99f0-af020d1acdb4
Litfulo
A medicinal product containing ritlecitinib, registered in United States by Pfizer Laboratories Div Pfizer Inc.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ritlecitinib
- Manufacturer
- Pfizer Laboratories Div Pfizer Inc
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc11006903342828 CAPSULE in 1 BOTTLE (0069-0334-28)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ritlecitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLITFULOPfizer Europe MA EEIG, Bruxelles
- SwitzerlandLitfulo 50 mg, HartkapselnPfizer AG
- SpainLITFULO 50 MG CAPSULAS DURASPfizer Europe Ma Eeig
- FinlandLitfuloPfizer Europe MA EEIG
- FranceLITFULO 50 mg, gélulePFIZER EUROPE MA EEIG (BELGIQUE)
- BelgiumLitfulo 50 mgPfizer Europe MA
- IrelandLitfulo 50 mg hard capsulesPfizer Europe MA EEIG
- IcelandLitfuloPfizer Europe MA EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Litfulo
- Liechtenstein · Litfulo
- Norway · Litfulo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/31762470-269f-4eb6-89bc-c2ab3d682d15 GET /v1/drugs/31762470-269f-4eb6-89bc-c2ab3d682d15?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 5
},
"productid": "0069-0334_09443f87-c2da-46a4-99f0-af020d1acdb4",
"productndc": "0069-0334",
"dosage_form": "CAPSULE",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "RITLECITINIB TOSYLATE",
"proprietary_name": "Litfulo",
"active_ingred_unit": "mg/1",
"application_number": "NDA215830",
"marketing_category": "NDA",
"nonproprietary_name": "ritlecitinib",
"start_marketing_date": "20230706",
"active_numerator_strength": "50"
}See everything about ritlecitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.